How would you consider use of high dose IL-2 for metastatic renal cell carcinoma, in light of novel checkpoint therapy combinations now available?  

In the context of significant favorable impacts of PD-1 combinations for RCC treatment, including [in alphabetical order] axitinib/avelumab, axitinib/pembrolizumab, cabozantinib/nivolumab, and ipilumimab/nivolumab and [to this point non-randomized data for lenvatinib/pembrolizumab], there remains th...